NCT03251768View on ClinicalTrials.gov

Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

July 23, 2018

Study Completion Date

April 24, 2019

Conditions
Chemotherapy-induced Neutropenia
Interventions
DRUG

rHSA-GCSF 2.4mg

Human Serum Albumin GCSF 2.4mg at day 3 and day 7

DRUG

GCSF

GCSF 5 mcg/kg/day

Trial Locations (1)

100021

Chinese Academy of Medical Sciences Cancer Hospital, Beijing

All Listed Sponsors
lead

Tianjin SinoBiotech Ltd.

INDUSTRY

NCT03251768 - Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients | Biotech Hunter | Biotech Hunter